GlassScriptPhysician profile
Elyra Figueroa
NPI 1760686034
$11,293.04
in general payments reported to CMS, 2019-2025
33 companies · $3,181 in 2025
The $3,181 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $852 · 2021: $1,144 · 2022: $1,380 · 2023: $1,512 · 2024: $2,602 · 2025: $3,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,985 · Education: $296 · Consulting Fee: $14.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,985.18 |
| Education | $296.04 |
| Consulting Fee | $14.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,877.83 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $1,384.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,286.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,234.03 | 2019-2025 | Dupixent |
| Csl Behring | $1,017.21 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $486.43 | 2021-2025 | |
| Abbvie INC. | $414.46 | 2021-2024 | |
| Pfizer INC. | $395.01 | 2019-2025 | |
| Allergan, INC. | $354.29 | 2019-2020 | |
| Genentech USA, INC. | $346.42 | 2021-2025 | Xolair |
| Optinose US, INC. | $298.95 | 2019-2025 | |
| Kaleo, INC. | $293.82 | 2019-2024 | Auvi-Q |
| Galderma Laboratories, L.P. | $284.82 | 2019-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $222.84 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.56 | 2024-2025 | Eohilia, Cuvitru, Hyqvia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $160.44 | 2025 | Neffy |
| Amgen INC. | $156.27 | 2022-2025 | Tezspire |
| Lilly USA, LLC | $141.70 | 2020-2025 | Ebglyss, Taltz |
| Novo Nordisk INC | $123.55 | 2025 | Ozempic |
| Biohaven Pharmaceuticals, INC. | $114.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $105.56 | 2020 | |
| Grifols USA, LLC | $83.33 | 2020-2024 | Xembify |
| Convatec INC. | $78.91 | 2021 | |
| Kedrion Biopharma, INC. | $40.31 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Mylan Specialty L.P. | $33.15 | 2020 | |
| Azurity Pharmaceuticals, INC. | $33.00 | 2025 | Alvesco |
| Insmed, INC. | $23.98 | 2025 | Brinsupri |
| Biocryst US Sales Co., LLC | $21.95 | 2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $21.06 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $18.42 | 2022 | |
| Adma Biomanufacturing LLC | $14.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.35 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyra Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.